Renovo Concepts
San Antonio, US · Founded 2016 · Delaware corporation
Renovo Concepts develops Mechanical Tissue Resuscitation (MTR), a therapy that applies controlled sub-atmospheric pressure to remove excess fluid from damaged brain, heart, and spinal tissue in order to reduce secondary injury. Its first clinical indication is traumatic brain injury, and the company is conducting first-in-human clinical trials.
Founders & leadership
MM
Michael MorykwasCo-inventor of MTR
LL
Linda LoftusTreasurer and Secretary
LA
Louis ArgentaCo-inventor of MTR
SV
Silbiano V. Gonzales, Jr.Named on SEC filing
CI
Charles I. Biltz, Jr.Named on SEC filing
FD
Frank DilazzaroNamed on SEC filing
Board
WM
William MayerBoard director
ML
Martin LandonBoard director
Reported raises · per SEC filings
Form D private placements$11.3M disclosed across 7 rounds · 2018–2023
▶$7.4MraisedMay 2026 · 7 investors · Other Health CareRule 506(b)
▶$7.4MraisedMay 2026 · 7 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Michael MorykwasExecutive Officer, Director
- Linda LoftusExecutive Officer
- William MayerDirector
- Louis ArgentaExecutive Officer
- Martin LandonDirector
- Offering amount
- $8.6M
- Amount sold
- $7.4M
- Minimum investment
- $10K
- Proceeds to insiders
- $540K
- First sale
- Apr 2023
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$420.1KraisedMay 2022 · 5 investors · Other Health CareRule 506(b)
▶$420.1KraisedMay 2022 · 5 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Michael MorykwasDirector
- Mark StandefordExecutive Officer, Director
- Louis ArgentaDirector
- William MayerDirector
- Martin LandonDirector
- Offering amount
- $2M
- Amount sold
- $420.1K
- First sale
- May 2022
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$1.3MraisedJun 2020 · 2 investors · Other Health CareRule 506(b)
▶$1.3MraisedJun 2020 · 2 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Charles I. Biltz, Jr.Executive Officer, Director
- Martin J. LandonDirector
- Houston CowanDirector
- Louis ArgentaDirector
- Michael MorykwasExecutive Officer, Director
- Silbiano V. Gonzales, Jr.Executive Officer, Director
- Offering amount
- $10M
- Amount sold
- $1.3M
- First sale
- May 2020
- Incorporated
- Corporation, Delaware, 2016
- Federal exemptions
- 06b
▶$350KraisedMar 2020 · 2 investors · Other Health CareRule 506(b)
▶$350KraisedMar 2020 · 2 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Martin J. LandonDirector
- Charles I. Biltz, Jr.Executive Officer, Director
- Louis ArgentaDirector
- Silbiano V. Gonzales, Jr.Executive Officer, Director
- Michael MorykwasExecutive Officer, Director
- Houston CowanDirector
- Offering amount
- $700K
- Amount sold
- $350K
- First sale
- Feb 2020
- Incorporated
- Corporation, Delaware, 2016
- Federal exemptions
- 06b
▶$925KraisedSep 2019 · 6 investors · Other Health CareRule 506(b)
▶$925KraisedSep 2019 · 6 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Silbiano V. Gonzales, Jr.Executive Officer, Director
- Frank DilazzaroExecutive Officer, Director
- Christopher FashekDirector
- Michael MorykwasDirector
- Charles I. Biltz, Jr.Executive Officer, Director
- Louis ArgentaDirector
- Offering amount
- $3M
- Amount sold
- $925K
- First sale
- Sep 2018
- Incorporated
- Corporation, Delaware, 2016
- Federal exemptions
- 06b
▶$400KraisedOct 2018 · 2 investors · Other Health CareRule 506(b)
▶$400KraisedOct 2018 · 2 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Silbiano V. Gonzales, Jr.Executive Officer, Director
- Michael MorykwasDirector
- Charles I. Biltz, Jr.Executive Officer, Director
- Louis ArgentaDirector
- Frank DilazzaroExecutive Officer, Director
- Offering amount
- $1.8M
- Amount sold
- $400K
- First sale
- May 2018
- Incorporated
- Corporation, Delaware, 2016
- Federal exemptions
- 06b
▶$500KraisedOct 2018 · 2 investors · Other Health CareRule 506(b)
▶$500KraisedOct 2018 · 2 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Frank DilazzaroExecutive Officer, Director
- Silbiano V. Gonzales, Jr.Executive Officer, Director
- Louis ArgentaDirector
- Michael MorykwasDirector
- Charles I. Biltz, Jr.Executive Officer, Director
- Offering amount
- $500K
- Amount sold
- $500K
- First sale
- Feb 2018
- Incorporated
- Corporation, Delaware, 2016
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 2
by search overlapRenovo Rx8 shared keywordsRenovoRx develops targeted oncology therapies and commercializes the RenovoCath, an FDA-cleared drug-delivery device for intra-arterial chemotherapy administration in cancer treatment. The company is conducting Phase III clinical trials of its proprietary TAMP therapy platform for treating locally advanced pancreatic cancer with improved safety and efficacy compared to systemic chemotherapy.
LeadIQ6 shared keywordsLeadIQ offers a company search tool that provides B2B company profiles with data such as revenue, employee count, funding, and contact information to help sales teams find decision makers and build pipeline.
Companies competing with Renovo Concepts for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Frequently asked questions
- What does Renovo Concepts do?
- Renovo Concepts develops Mechanical Tissue Resuscitation (MTR), a therapy that applies controlled sub-atmospheric pressure to remove excess fluid from damaged brain, heart, and spinal tissue in order to reduce secondary injury. Its first clinical indication is traumatic brain injury, and the company is conducting first-in-human clinical trials.
- How much funding has Renovo Concepts raised?
- Renovo Concepts has disclosed $11.3M raised across 7 rounds.
- Where is Renovo Concepts headquartered?
- Renovo Concepts is headquartered in San Antonio, US.